{"entity":{"id":"da-remternetug","kind":"drug","name":"Remternetug","aka":[],"tldr":"Remternetug is an investigational amyloid antibody. It is not approved. Trial eligibility is not a treatment recommendation.","summary":"Listed so the pipeline layer of the Alzheimer’s page has a concrete next antibody. Risks should not be copied from lecanemab or donanemab by assumption.","status":"phase-3","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov search","url":"https://clinicaltrials.gov/search?intr=remternetug"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease"],"sections":[],"technologies":[],"targets":["da-target-amyloid-beta"],"drugs":[],"companies":["da-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"LY3372993","modality":"mAb","mechanism":"Investigational amyloid-directed antibody.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/da-remternetug/","neighbours":{"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"}],"target":[{"id":"da-target-amyloid-beta","kind":"target","name":"Amyloid-beta","route":"/targets/da-target-amyloid-beta/"}],"company":[{"id":"da-lilly","kind":"company","name":"Eli Lilly","route":"/companies/da-lilly/"}],"roadmap":[{"id":"da-roadmap-anti-amyloid","kind":"roadmap","name":"Anti-amyloid medicines","route":"/roadmaps/da-roadmap-anti-amyloid/"}]}}